2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pre‐operative high‐frequency ultrasound: a reliable management tool in auricular and nasal non‐melanoma skin cancer

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Background and objectives

          The knowledge of depth infiltration in non‐melanoma skin cancer (NMSC) using pre‐operative ultrasound could enable clinicians to choose the most adequate therapeutic approach, avoiding unnecessary surgeries and expensive imaging methods, delaying diagnosis and treatment. Our single‐center retrospective study determined the usefulness of high‐frequency ultrasound (HFUS) for depth infiltration assessment in auricular and nasal NMSC and assessed the subsequent change in therapeutic approach.

          Patients and Methods

          In 60 NMSC cases, we assessed the accuracy of HFUS in cartilaginous/bone infiltration detection as well as the correlation of sonographic and histological parameters.

          Results

          In 16.6% of cases, a deep cartilaginous/bone involvement or locoregional disease was identified pre‐operatively, resulting in a changed therapeutical scheme of radio‐immunological treatment rather than surgery. In two cases, pre‐operative HFUS identified local cartilage infiltration, reducing the number of surgical procedures. Forty‐eight remaining lesions with no depth infiltration were excised; a correlation of > 99% between the histologic and sonographic tumor depth (p<0.001) was found.

          Conclusions

          Pre‐surgical HFUS influences the therapeutic management in NMSC by detecting subclinical involvement of deeper structures, avoiding more extensive diagnostics, reducing costs, and improving healthcare quality. High‐frequency ultrasound should be implemented in dermatosurgery before tumor excision for optimized therapy and improved patient counseling.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

          No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because the mutation burden of the tumor is high and the disease risk is strongly associated with immunosuppression. In the dose-escalation portion of the phase 1 study of cemiplimab, a deep and durable response was observed in a patient with metastatic cutaneous squamous-cell carcinoma.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

            Cemiplimab has shown substantial antitumour activity in patients with metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous squamous cell carcinoma have poor prognosis with conventional systemic therapy. We present a primary analysis of the safety and antitumour activity of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines

              Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer collaborated to develop recommendations on diagnosis and treatment of BCC. A new classification into 'easy-to-treat (common) BCC and 'difficult-to-treat' BCC is proposed. Diagnosis is based on clinicodermatoscopic features for 'easy-to-treat' BCCs. Histopathological confirmation is mandatory in ambiguous lesions and in BCCs located in high-risk areas. The first-line treatment of 'easy-to-treat' BCC is complete surgery. Microscopically controlled surgery shall be offered for high-risk BCC, recurrent BCC and BCC in critical anatomical sites. Topical therapies (5% imiquimod, 5% fluorouracil) and destructive approaches (curettage, electrocautery, cryotherapy, laser ablation) should be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial BCC and thin nodular BCC. The therapy for a 'difficult-to-treat' BCC should preferentially be discussed by a multidisciplinary tumour board. Hedgehog inhibitors, vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCCs. Immunotherapy with anti-programmed cell death 1 (PD-1) antibodies is a promising therapeutic option, currently being investigated in clinical trials. Radiotherapy represents a valid alternative to surgery for BCC on the face, especially in elderly patients. In patients with naevoid basal cell carcinoma syndrome (NBCCS), close surveillance and regular skin examinations are required to diagnose and treat BCCs at early stage. Long-term follow-up is recommended in patients with high-risk BCC subtypes, high-risk sites, multiple BCCs and NBCCS.
                Bookmark

                Author and article information

                Contributors
                Journal
                JDDG: Journal der Deutschen Dermatologischen Gesellschaft
                J Deutsche Derma Gesell
                Wiley
                1610-0379
                1610-0387
                March 2024
                January 20 2024
                March 2024
                : 22
                : 3
                : 357-365
                Affiliations
                [1 ] Clinic of Dermatology and Allergology University Clinic Ulm Ulm Germany
                [2 ] Department of Dermatology School of Medicine Pontificia Universidad Catolica de Chile Santiago Chile
                [3 ] Department of Dermatology Faculty of Medicine Universidad de Chile Santiago Chile
                [4 ] Institute for Diagnostic Imaging and Research of the Skin and Soft Tissues Santiago Chile
                [5 ] Department of Radiology Istituto Diagnostico Varelli Naples Italy
                [6 ] Department of Medical Imaging “Prof. Dr. Octavian Fodor” Regional Institute of Gastroenterology and Hepatology Cluj‐Napoca Romania
                [7 ] Department of Anatomy and Embriology “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj‐Napoca Romania
                [8 ] Department of Maxillofacial Surgery and Implantology “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj‐Napoca Romania
                [9 ] Department of Neuroscience “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj‐Napoca Romania
                [10 ] Clinic of Dermatology and Venerology Cluj‐Napoca County Hospital Cluj‐Napoca Romania
                Article
                10.1111/ddg.15308
                38243870
                5f31806f-4c12-4110-916b-d407aa2a5763
                © 2024

                http://creativecommons.org/licenses/by-nc-nd/4.0/

                History

                Comments

                Comment on this article